- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02373722
Website Application Based Education and Text Messaging in Improving Skin Wound Care in Patients Undergoing Mohs Surgery
Web App Based Patient Education in Mohs Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To create a web application which will educate dermatologic surgery patients prior to their operations with educational videos.
SECONDARY OBJECTIVES:
I. To create and evaluate a web based system to send wound care instructions to patients by text message after their operation.
II. Qualitative comments from participants and research staff concerning the feasibility of this approach and the use of Fitbit activity trackers as a means to monitor movement restriction.
III. The rate of adverse events.
OUTLINE: Patients are randomized to 1 of 4 groups.
GROUP I: Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly twice daily (BID) to the wound area.
GROUP II: Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area.
GROUP III: Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
GROUP IV: Patients receive no video or text messages. Patients receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
After completion of study, patients are followed up at 1 week.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Comprehensive Cancer Center of Wake Forest University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is undergoing Mohs surgery
- Subject is capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed
- The subject is able to complete the study and comply with study instructions, including attending all study visits
- The patient has a cell phone capable of receiving text messages
Exclusion Criteria:
- The patient is not indicated for Mohs surgery
- Inability to complete all study-related visits
- Non-English speaking patients
- The patient cannot receive text messages
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group I (video, text message)
Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery.
Patients also receive instructions to reduce movement and use a Fitbit activity tracker.
Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
|
Ancillary studies
Ancillary studies
Receive text messages
Undergo Mohs surgery
Watch website application based educational video
Watch website application based educational video
Other Names:
Use Fitbit
Applied to the wound area
Other Names:
|
|
Experimental: Group II (educational video)
Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker.
Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area
|
Ancillary studies
Ancillary studies
Undergo Mohs surgery
Watch website application based educational video
Watch website application based educational video
Other Names:
Use Fitbit
Applied to the wound area
Other Names:
|
|
Experimental: Group III (text message)
Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker.
Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
|
Ancillary studies
Ancillary studies
Receive text messages
Undergo Mohs surgery
Use Fitbit
Applied to the wound area
Other Names:
|
|
Experimental: Group IV (control)
Patients receive no video or text messages.
Patients receive instructions to reduce movement and use a Fitbit activity tracker.
Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
|
Ancillary studies
Ancillary studies
Undergo Mohs surgery
Use Fitbit
Applied to the wound area
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Preoperative anxiety score
Time Frame: Before surgery
|
The preoperative anxiety scores of patients randomized to receive or not receive the educational video will be compared using a t-test or appropriate non-parametric test (Wilcoxon Rank Sum or Sign test) based on the distribution of the scores.
|
Before surgery
|
|
Patient knowledge score
Time Frame: Up to 1 week after completion of study
|
Patient knowledge scores of patients randomized to receive or not receive the educational video will be compared using a t-test or appropriate non-parametric test (Wilcoxon Rank Sum or Sign test) based on the distribution of the scores.
|
Up to 1 week after completion of study
|
|
Medication adherence
Time Frame: Up to 1 week after completion of study
|
The mean number of times the medication was applied will be compared for the three intervention groups versus the control group.
|
Up to 1 week after completion of study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient satisfaction score
Time Frame: Up to 1 week after completion of study
|
Patient satisfaction scores across the four randomization groups will be compared using analysis of variance (ANOVA) methods.
|
Up to 1 week after completion of study
|
|
Mobility adherence as measured by Fitbit monitor
Time Frame: Up to 1 week after completion of study
|
Compare the average number of steps taken each day between groups and the cumulative number of steps taken over the whole week using ANOVA methods.
Percentage of patients with average daily activity below 2500 steps will be compared using the Chi-Squared or Fisher's Exact test.
All three intervention groups will be compared to the control group.
|
Up to 1 week after completion of study
|
|
Incidence of adverse events
Time Frame: Up to 1 week after completion of study
|
The proportion of patients reporting adverse events will be compared using chi-squared tests or Fisher's exact tests, depending on the expected frequency of events.
Comparisons will be made for those given versus not given the surgery education mobile app and then for those given versus not given text messages.
To look at all four groups independently, a global statistic will be initially calculated.
If significant, comparisons between the four groups will be made.
|
Up to 1 week after completion of study
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel Pearce, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00028840
- P30CA012197 (U.S. NIH Grant/Contract)
- NCI-2015-00217 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CCCWFU 01714 (Other Identifier: Comprehensive Cancer Center of Wake Forest University)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Skin Neoplasm
-
Mayo ClinicRecruitingSoft Tissue Neoplasm | Recurrent Malignant Skin Neoplasm | Recurrent Malignant Soft Tissue Neoplasm | Skin Neoplasm | Metastatic Malignant Skin Neoplasm | Metastatic Malignant Soft Tissue NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Skin Neoplasm | Metastatic Malignant Skin NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Malignant Thoracic Neoplasm | Malignant Head and Neck Neoplasm | Malignant Breast NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingMalignant Solid Neoplasm | Endocrine Gland Neoplasms | Breast Carcinoma | Malignant Female Reproductive System Neoplasm | Malignant Thoracic Neoplasm | Malignant Head and Neck Neoplasm | Malignant Digestive System Neoplasm | Central Nervous System Neoplasm | Soft Tissue Neoplasm | Skin Neoplasm | Malignant... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMalignant Skin Neoplasm | Skin Disorder | Skin NeoplasmUnited States
-
National Cancer Institute, ThailandCompleted
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Istanbul Aydın UniversityCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Université Catholique de LouvainRecruiting
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingCOVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingEndometrial Carcinoma | Malignant Uterine Neoplasm | Uterine Corpus Cancer | Uterine Corpus SarcomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedBreast Cancer | Prostate CancerUnited States